solidcolours / iStockphoto.com
Sandoz has entered into a development and commercialisation agreement with pharmaceutical company Durect to develop the drug Posimir (Saber-bupivacaine).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sandoz, Durect, agreement, m&a, development, commercialisation, Posimir, pain relief